Glucocorticoids and osteoporosis;Glukokortikoidy a osteoporóza

Vnitrni Lekarstvi

Volumn 53, Issue 7-8, 2007, Pages 831-840

  Zikán, Vít ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Bisphosphonates; Bone formation; Bone metabolism; Bone resorption; Calcium; D vitamin; Estrogens; Glucocorticoids; Individual sensitivity to glucocorticoids; Osteoanabolic treatment; Osteoporosis; Testosterone

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; PREDNISONE; VITAMIN D;

APOPTOSIS; BONE DENSITOMETRY; BONE DENSITY; BONE DEVELOPMENT; BONE METABOLISM; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; GENE REPRESSION; HORMONE SENSITIVITY; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUMBAR SPINE; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOPOROSIS; PREMENOPAUSE; REVIEW; VERTEBRA FRACTURE;

BONE AND BONES; BONE RESORPTION; GLUCOCORTICOIDS; HUMANS; OSTEOGENESIS; OSTEOPOROSIS;

EID: 34548501084     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Kanis JA, Johansson H, Oden A et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893-899.
2. van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93: 105-111.
3. Reid IR Glucocorticoid-induced osteoporosis: assessment and treatment. J Clin Densitom 1998; 1: 65-73.
4. van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000.
5. Israel E, Banerjee TR, Fitzmaurice GM et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001; 345: 941-947.
6. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004; 15: 323-328.
7. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med 2005; 257: 374-384.
8. Angeli A, Guglielmi G, Dovio A et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006; 39: 253-259.
9. Dalle Carbonare L, Arlot ME, Chavassieux PM et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001; 16: 97-103.
10. Francucci CM, Pantanetti P, Garrapa GG et al. Bone metabolism and mass in women with Cushing's syndrome and adrenal incidentaloma. Clin Endocrinol (Oxf) 2002; 57: 587-593.
11. Cortet B, Cortet C, Blanckaert F et al. Quantitative ultrasound of bone and markers of bone turnover in Cushing's syndrome. Osteoporos Int 2001; 12: 117-123.
12. Ton FN, Gunawardene SC, Lee H et al. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005; 20: 464-470.
13. Pearce G, Ryan PF, Delmas PD et al. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol 1998; 37: 292-299.
14. LoCascio V, Bonucci E, Imbimbo B et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990; 8: 39-51.
15. Weinstein RS, Jilka RL, Parfitt AM et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of the deleterious effects on bone. J Clin Invest 1998; 102: 274-282.
16. Manning PJ, Evans MC, Reid IR Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol (Oxf) 1992; 36: 229-234.
17. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13: 777-787.
18. van Staa TP, Leufkens HG, Abenhaim L et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxf) 2000; 39: 1383-1389.
19. van Staa TP, Geusens P, Pols HA et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005; 98: 191-198.
20. Weinstein RS, Chen JR, Powers CC et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002; 109: 1041-1048.
21. Nuttall ME, Gimble JM Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone 2000; 27: 177-184.
22. Nuttall ME, Patton AJ, Olivera DL et al. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J Bone Miner Res 1998; 13: 371-382.
23. Chang DJ, Ji C, Kim KK et al. Reduction in transforming growth factor beta receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid. J Biol Chem 1998; 273: 4892-4896.
24. Li X, Jin L, Cui Q et al. Steroid effects on osteogenesis through mesenchymal cell gene expression. Osteoporos Int 2005; 16: 101-108.
25. Sciaudone M, Gazzerro E, Priest L et al. Notch 1 impairs osteoblastic cell differentiation. Endocrinology 2003; 144: 5631-5639.
26. Deregowski V, Gazzerro E, Priest L et al. Notch 1 overexpression inhibits osteohistogenesis by suppressing Wnt/β-catenin but not bone morphogenetic protein signaling. J Biol Chem 2006; 281: 6203-6210.
27. Smith E, Frenkel B. Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3β-dependent and-independent manner. J Biol Chem 2005; 280: 2388-2394.
28. Ohnaka K, Taniguchi H, Kawate H et al. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 2004; 318: 259-264.
29. Delany AM, Canalis E. Transcriptional repression of insulin-like growth factor I by glucocorticoids in rat bone cells. Endocrinology 1995; 136: 4776-4781.
30. Cui Q, Wang GJ, Balian G. Steroid-induced adipogenesis in a pluripotential cell line from bone marrow. J Bone Joint Surg Am 1997; 79: 1054-1063.
31. O'Brien CA, Jia D, Plotkin LI et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145: 1835-1841.
32. Weinstein RS Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000; 108: 153-164.
33. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000; 85: 2907-2912.
34. Jia D, O'Brien CA, Stewart SA et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006; 147: 5592-5599.
35. Rubin MR, Bilezikian JP. Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 2002; 87: 4033-4041.
36. Hofbauer LC, Gori F, Riggs BL et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140: 4382-4389.
37. Rubin J, Biskobing DM, Jadhav L et al. Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology 1998; 139: 1006-1012.
38. Dovio A, Perazzolo L, Osella G et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 2004; 89: 4923-4928.
39. Dempster DW, Moonga BS, Stein LS et al. Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis. J Endocrinol 1997; 154: 397-406.
40. Gennari C. Differential effect of glucocorticoids on calcium absorption and bone mass. Br J Rheumatol 1993; 32(Suppl 2): 11-14.
41. Bonadonna S, Burattin A, Nuzzo M et al. Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol 2005; 152: 199-205
42. Doga M, Bonadonna S, Giustina A. Glucocorticoids and bone: cellular, metabolic and endocrine effects. Hormones (Athens) 2004; 3: 184-190.
43. Manelli F, Giustina A. Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab 2000; 11: 79-85.
44. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998; 19: 717-797.
45. Giustina A, Bussi AR, Jacobello C et al. Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 1995; 80: 122-129.
46. Delany AM, Durant D, Canalis E. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol 2001; 15: 1781-1789.
47. Gabbitas B, Pash JM, Delany AM et al. Cortisol inhibits the synthesis of insulin-like growth factor-binding protein-5 in bone cell cultures by transcriptional mechanisms. J Biol Chem 1996; 271: 9033-9038.
48. van Rossum EF, Lamberts SW Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res 2004; 59: 333-357.
49. Cooper MS, Walker EA, Bland R et al. Expression and functional consequences of 11β-hydroxysteroid dehydrogenase activity in human bone. Bone 2000; 27: 375-381.
50. Draper N, Stewart PM 11β-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 2005; 186: 251-271.
51. Tomlinson JW, Draper N, Mackie J et al. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. J Clin Endocrinol Metab 2002; 87: 57-62.
52. Cooper MS, Rabbitt EH, Goddard PE etal. Osteoblastic 11β- hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 2002; 17: 979-986.
53. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis. Arthritis Rheum 2001; 44: 1496-1503.
54. Royal College of Physicians. Glucocorticoid-induced Osteoporosis: guidelines for prevention and treatment. London: Royal College of Physicians 2002.
55. Růžičková O, Bayer M, Pavelka K et al. Doporučení pro prevenci a léčbu glukokortikoidy indukované osteoporózy u pacientů s revmatickým onemocněním (Společné stanovisko České revmatologické společnosti a Společnosti pro metabolická onemocnění skeletu). Čes Revmatol 2004; 12: 163-174.
56. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-1936.
57. Ichikawa F, Sato K, Nanjo M et al. Mouse primary osteoblasts express vitamin D3 25-hydroxylase mRNA and convert 1-α-hydroxyvitamin D3 into 1-α, 25 dihydroxyvitamin D3. Bone 1995; 16: 129-135.
58. Bouillon R, Van Cromphaut S, Carmeliet G. Intestinal calcium absorption: Molecular vitamin D mediated mechanisms. J Cell Biochem 2003; 88: 332-339.
59. Hoenderop JG, Muller D, Van Der Kemp AW et al. Calcitriol controls the epithelial calcium channel in kidney. J Am Soc Nephrol 2001; 12: 1342-1349.
60. Russell JD, Lettieri D, Sherwood LM Suppression by 1,25-(OH)2D of transcription of the parathyroid hormone gene. Endocrinology 1985; 119: 2864-2866.
61. Schacht E, Richy F, Reginster JY. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact 2005; 5: 273-284.
62. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002; 8: 174-179.
63. Li M, Healy DR, Simmons HA et al. Alfacalcidol restores cancellous bone in ovariectomized rats. J Musculoskelet Neuronal Interact 2003; 3: 39-46.
64. Shiraishi A, Takeda S, Masaki T et al. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 2000; 15: 770-779.
65. Ohnaka K, Tanabe M, Kawate H et al. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 2005; 329: 177-181.
66. Scharla SH, Strong DD, Mohan S et al. 1,25-Dihydroxyvitamin D3 differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts. Endocrinology 1991; 129: 3139-3146.
67. Hofbauer LC, Dunstan CR, Spelsberg TC et al. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998; 250: 776-781.
68. van Driel M, Koedam M, Buurman CJ et al. Evidence for auto/paracrine actions of vitamin D in bone: 1α-hydroxylase expression and activity in human bone cells. FASEB J 2006; 20: 2417-2419.
69. de Nijs RN, Jacobs JW, Lems WF et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006; 355: 675-684.
70. Scharla SH, Schacht E, Lempert UG. Alfacalcidol versus plain vitamin D in inflammation induced bone loss. J Rheumatol Suppl 2005; 76: 26-32.
71. Weinstein RS, Jia D, Powers CC et al. The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 2004; 145: 1980-1987.
72. Pearce G, Tabensky DA, Delmas PD et al. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 2005; 83: 801-806.
73. Kousteni S, Chen JR, Bellido TM et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 2002; 298: 843-846.
74. Gu G, Hentunen TA, Nars M et al. Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis 2005; 10: 583-595.
75. Plotkin LI, Aguirre JI, Kousteni S et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 2005; 280: 7317-7325.
76. Mann V, Huber C, Kogianni G et al. The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone 2007; 40: 674-684.
77. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992; 7: 1063-1069.
78. Crawford BA, Liu PY, Kean MT et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003; 88: 3167-3176.
79. Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292-299.
80. Cummings SR. How drugs decrease fracture risk: lessons from trials. J Musculoskelet Neuronal Interact 2002; 2: 198-200.
81. Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 2006; 39: 443-452.
82. Patlas N, Golomb G, Yaffe P et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999; 60: 68-73.
83. Franchimont N, Canalis E. Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease. Autoimmun Rev 2003; 2: 224-228.
84. Nishida S, Yamaguchi A, Tanizawa T et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 1994; 15: 717-723.
85. Jilka RL, Weinstein RS, Bellido T et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-446.
86. Pfeilschifter J, Laukhuf F, Muller-Beckmann B et al. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor β 1 in rat bone. J Clin Invest 1995; 96: 767-774.
87. Tobimatsu T, Kaji H, Sowa H et al. Parathyroid hormone increases β-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology 2006; 147: 2583-2590.
88. Lane NE, Sanchez S, Modin GW et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998; 102: 1627-1633.